InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) Short Interest Update

InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) was the target of a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 166,200 shares, a growth of 6.7% from the June 30th total of 155,700 shares. Based on an average daily volume of 57,400 shares, the short-interest ratio is currently 2.9 days. Approximately 0.9% of the shares of the company are sold short.

Insider Buying and Selling at InfuSystem

In other news, Director Ralph F. Boyd, Jr. bought 4,000 shares of the stock in a transaction dated Thursday, May 23rd. The stock was purchased at an average cost of $7.13 per share, for a total transaction of $28,520.00. Following the transaction, the director now owns 6,000 shares of the company’s stock, valued at $42,780. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Ralph F. Boyd, Jr. purchased 4,000 shares of InfuSystem stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average price of $7.13 per share, with a total value of $28,520.00. Following the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $42,780. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Andrew Gendron bought 5,000 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were purchased at an average cost of $6.54 per share, with a total value of $32,700.00. Following the completion of the transaction, the director now owns 65,000 shares in the company, valued at $425,100. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 13,000 shares of company stock valued at $87,300. Company insiders own 10.20% of the company’s stock.

Hedge Funds Weigh In On InfuSystem

A number of hedge funds have recently made changes to their positions in INFU. Kings Path Partners LLC acquired a new position in shares of InfuSystem in the 2nd quarter worth approximately $514,000. Panagora Asset Management Inc. bought a new stake in shares of InfuSystem during the second quarter valued at about $208,000. Bank of New York Mellon Corp boosted its holdings in shares of InfuSystem by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the medical instruments supplier’s stock valued at $641,000 after acquiring an additional 5,391 shares in the last quarter. ARS Investment Partners LLC raised its stake in shares of InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the medical instruments supplier’s stock worth $229,000 after buying an additional 3,422 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of InfuSystem in the 2nd quarter worth approximately $272,000. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Trading Down 5.1 %

Shares of INFU stock traded down $0.35 during midday trading on Thursday, hitting $6.55. The company had a trading volume of 23,073 shares, compared to its average volume of 50,606. The company has a market capitalization of $139.52 million, a P/E ratio of -690,000.00 and a beta of 1.44. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.57. InfuSystem has a 52-week low of $6.25 and a 52-week high of $11.44.

InfuSystem (NYSEAMERICAN:INFU) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported ($0.05) earnings per share for the quarter. The firm had revenue of $32.00 million during the quarter. InfuSystem had a return on equity of 0.16% and a net margin of 0.07%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. StockNews.com cut shares of InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th. Lake Street Capital upgraded shares of InfuSystem to a “strong-buy” rating in a research note on Thursday, May 9th.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.